Repositioning Candidate Details
| Candidate ID: | R1364 |
| Source ID: | DB11323 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Glycol salicylate |
| Synonyms: | 2-hydroxybenzoic acid 2-hydroxyethyl ester; 2-hydroxyethyl 2-oxidanylbenzoate; 2-hydroxyethyl salicylate; Ethylene glycol monosalicylate; Ethylene glycol salicylate; Glycol salicylate |
| Molecular Formula: | C9H10O4 |
| SMILES: | OCCOC(=O)C1=CC=CC=C1O |
| Structure: |
|
| DrugBank Description: | Glycol salicylate, also known as _2-hydroxyethyl salicylate_, is a benzoate ester formed from the condensation of the carboxy group of salicylic acid with one of the hydroxy groups of ethylene glycol. It is found as an active ingredient and topical analgesic in patches used to provide relief for mild to moderate muscle and joint pain . This drug belongs to the _salicylate_ group of drugs, which are used as analgesic agents for the treatment of mild to moderate pain . Glycol salicylate (GS), composed of salicylic acid (SA) and ethylene glycol, is a non-steroidal anti-inflammatory drug . This ingredient is an important component of many topical creams and sprays for the relief of aches, pains, and stiffness of the muscles, joints, and tendons . |
| CAS Number: | 87-28-5 |
| Molecular Weight: | 182.175 |
| DrugBank Indication: | This drug is only recommended for topical usages for the relief of muscular and rheumatic pain in human and animals . |
| DrugBank Pharmacology: | Temporarily relieves minor to moderate aches and pains . Works with ingredients such as menthol, which has counter-irritant properties . Counter-irritants are externally applied, and lead to irritation or mild inflammation of the skin to relieve pain in muscles or joints by reducing inflammation in deeper adjacent structures . Counter-irritants relieve pain by disrupting the brain from receiving pain signals resulting from conditions such as osteoarthritis (OA) or injuries such as sprains or strains. These agents may cause vasodilatation or skin irritation, leading to a false sensation of heat or warmth . |
| DrugBank MoA: | Similar to other salicylates. Salicylates and other analgesics and anti-inflammatory drugs, particularly the non-steroidal anti-inflammatory drugs (NSAID) mainly used in rheumatology, inhibit cyclooxygenase, therefore reducing prostaglandin synthesis . |
| Targets: | Prostaglandin G/H synthase 1 antagonist; Prostaglandin G/H synthase 2 antagonist |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I15 | 1290 | Bone disease | A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. http://en.wikipedia.org/wiki/Bone_disease | disease of anatomical entity/ musculoskeletal system disease/connective tissue disease | Details |